The Cost of Chronic Disease and the Future of Treatment

Chronic Disease Burden and Epidemiology

• Prevalence Trends: The MENA region faces a growing chronic disease epidemic driven by lifestyle factors, specifically with 35 million adults living with diabetes (approx. 9.2% prevalence), a figure projected to rise 81% by 2045.
• Regional Specifics: In the UAE, diabetes prevalence is estimated at one in five (20%) to one in four (25%) of the adult population, with an additional ~50% falling into the pre-diabetes category.
• Obesity Correlation: Between one-third and one-fourth of the adult MENA population has obesity; combining overweight and obesity categories, nearly two-thirds of adults in the region are affected, comparable to the 72% rate in the United States.
• Causal Link: Obesity is a direct causal factor for chronic disease, making individuals with a BMI in the obesity category 3.4 times more likely to develop type 2 diabetes compared to those with a normal weight.
• Economic Impact: Healthcare spending for diabetes in the MENA region reached $20.5 billion in 2017, with significant projected increases by 2045 driving the condition into the realm of primary economic concern.
• Disease Scope: Major chronic conditions in the region include coronary heart disease, congestive heart failure, stroke, kidney disease, arthritis, and cancer, with cancer incidence rising as a secondary major threat following cardiovascular disease.

Data Collection and Surveillance Strategies

• US Methodology: The CDC utilizes the Behavioral Risk Factor Surveillance System (BRFSS), expanding from landline-based surveys in the 1980s to mobile-phone surveys covering all 50 states, collecting data from over 400,000 adults annually.
• Global Field Surveys: The "Steps" survey, a WHO-led household-based methodology, provides high-quality data every three to five years but is resource-intensive, prompting the need for more frequent monitoring tools.
• Mobile Innovation: The CDC's "Data for Health Initiative" partners with mobile carriers and governments to conduct frequent mobile phone surveys using open-source platforms (e.g., "Survey123") in countries like Zambia, Morocco, and Ecuador to gather annual data on risk factors.
• Zambia Case Study: A mobile survey in Zambia reached over 6,000 adults across eight languages via SMS and voice prompts, revealing that 80% of adults lack recommended fruit/vegetable intake and 80% consume excessive salt.
• Workforce Training: To improve data interpretation, the CDC supports Field Epidemiology Training Programs (dubbed "disease detectives") in Egypt, Iraq, Jordan, Morocco, Saudi Arabia, Yemen, Tunisia, and Pakistan to train national, regional, and frontline public health workers.

Precision Medicine and Genomic Challenges

• Data Bias: Current genomic research suffers from severe demographic bias, with 81% of data derived from European descent populations, leaving over 60% of the global population (Middle East, Asia, Africa) represented by less than 5% of genomic insights.
• Clinical Misinterpretation: Sumit Jamwar highlighted that mutations historically deemed "drivers" for disease in Caucasians (e.g., for epilepsy) were found to be benign genetic variations in healthy Indian cohorts, risking inappropriate treatment if applied without population-specific validation.
• Reference Range Limitations: Standard laboratory "normal ranges" are often based on Caucasian norms, leading to potential misdiagnosis in other populations (e.g., African-American muscle mass affecting creatinine levels; vitamin D and osteoporosis scoring in the UAE).
• Technological Disruption: The cost of DNA sequencing has dropped 2.7 million-fold in 15 years (from $2.7 billion/13 years to <$1,000/hours), with costs expected to reach $100, enabling the potential for sequencing every newborn.
• AI Integration: Artificial intelligence and machine learning capabilities have improved a million-fold in the last 30 years, allowing for the analysis of the 3 billion-word "book of life" to identify personalized risk factors and treatment responses.

Treatment, Prevention, and Future Outlook

• Primary Treatment Paradigm: Dr. Hawa Al-Mansouri emphasizes that lifestyle modification (weight loss and diet) remains the number one treatment for type 2 diabetes, preceding pharmaceutical interventions.
• Pharmaceutical Role: Pfizer prioritizes partnerships for patient education and awareness, citing that in Saudi Arabia, 55% of breast cancers were diagnosed at advanced stages due to low awareness regarding self-examination and screening.
• Precision Oncology: Treatment for non-small cell lung cancer is shifting toward mutation-specific therapies (e.g., ALK mutations), requiring advanced diagnostics to identify patients who respond to specific targeted drugs rather than organ-based categorization.
• Shift to "Prevention": The panel advocates for a systemic shift from "sick care" to "health care," urging governments and clinicians to focus on proactive prevention and risk mitigation rather than reactive treatment.
• Implementation Strategy: The future of precision medicine relies on simplifying complex genomic data into user-friendly tools (e.g., mobile apps checking drug-gene compatibility) to prevent "black box" decision-making by busy clinicians.
• Future Vision: Sumit Jamwar compares the current state of genomics to the internet in 1995, predicting a revolution where the next generation leverages data fluency to create mature, predictive health ecosystems.